Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $100.25 Average PT from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $100.25.

Several equities research analysts have issued reports on ESTA shares. TD Cowen increased their price target on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Mizuho lifted their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. increased their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Needham & Company LLC lifted their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a report on Thursday, August 6th.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $74.92 on Thursday. The firm’s 50 day simple moving average is $84.07 and its 200 day simple moving average is $74.91. Establishment Labs has a fifty-two week low of $36.53 and a fifty-two week high of $97.59. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -57.19 and a beta of 1.05. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.57) EPS. As a group, sell-side analysts forecast that Establishment Labs will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC raised its position in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after buying an additional 197,962 shares during the last quarter. California State Teachers Retirement System boosted its position in Establishment Labs by 8,625.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,930,124 shares of the company’s stock worth $165,624,000 after acquiring an additional 1,908,004 shares during the last quarter. BlackRock Inc. bought a new position in shares of Establishment Labs during the 2nd quarter worth approximately $135,752,000. Bamco Inc. NY grew its stake in shares of Establishment Labs by 21.5% during the 2nd quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock worth $38,761,000 after acquiring an additional 160,755 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.